

CIRM Funded Clinical Trials

A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers

Disease Area:	Leukemia
Investigator:	Thomas Kipps
Institution:	University of California, San Diego
CIRM Grant:	CLIN2-10192
Award Value:	\$18,292,674
Trial Sponsor:	University of California, San Diego
Trial Stage:	Phase 1/2
Trial Status:	Not yet recruiting
Targeted Enrollment:	156
ClinicalTrials.gov ID:	NCT03088878



Thomas Kipps

Details:

Cancer is a leading cause of death in California. Many cancers resist current therapies due to therapy-resistant cancer stem cells (CSCs). A team at UCSD is testing an antibody therapy called cirmtuzumab in a clinical trial study to treat a blood cancer, Chronic Lymphocytic Leukemia (CLL). The antibody recognizes and attaches to a protein on the surface of cancer stem cells. This attachment disables the protein which slows the growth of the leukemia and makes it more vulnerable to anti-cancer drugs. The team is also testing cirmtuzumab in combination with an approved cancer fighting drug called ibrutinib, to target cancer stem cells in a separate clinical trial. The aim is that combining cirmtuzumab with ibrutinib will improve cancer remission and long-term cancer control in patients.

Design:

Open label. Phase 1b dose finding, followed by Phase 2a.

Goal:

Evaluate dosing and complete response rate.

Updates:

This study is currently recruiting participants.

News Releases:

State's Stem Cell Agency Awards \$18.2 Million Grant for B Cell Cancer Clinical Trial
UCSD cancer clinical trial gets \$18.2 million

Source URL: <http://www.cirm.ca.gov/clinical-trial/phase-1b2a-study-ror1-targeting-monoclonal-antibody-cirmtuzumab-and-bruton-tyrosine>